KRAS oncogenic mutations are widespread in lung cancer and, because direct targeting of KRAS has proven to be challenging, KRAS-driven cancers lack effective therapies. One alternative strategy for developing KRAS targeted therapies is to identify downstream targets involved in promoting important malignant features, such as the acquisition of a cancer stem-like and metastatic phenotype. Based on previous studies showing that KRAS activates nuclear factor kappa-B (NF-κB) through inhibitor of nuclear factor kappa-B kinase β (IKKβ) to promote lung tumourigenesis, we hypothesized that inhibition of IKKβ would reduce stemness, migration and invasion of KRAS-mutant human lung cancer cells. We show that KRAS-driven lung tumoursphere-derived cells...
Trabajo presentado en el Ciclo de conferencias CIC, celebrada en modalidad virtual el 13 de mayo de ...
: Non-small cell lung cancer (NSCLC) represents the perfect paradigm of 'precision medicine' due to ...
A greater understanding of non–small-cell lung cancer at a molecular level has led to the identifica...
Objectives: The ability of tumor cells to drive angiogenesis is an important cancer hallmark that po...
Although oncogenic activation of NFkB has been identified in various tumors, the NFkB–activating kin...
Lung cancer is a highly mutated tumour type in which, if effective, cancer immunotherapies have prov...
Although oncogenic activation of NF kappa B has been identified in various tumors, the NF kappa B-ac...
Although oncogenic activation of NFkB has been identified in various tumors, the NFkB–activating kin...
For decades, KRAS mutant lung adenocarcinomas (LUAD) have been refractory to therapeutic strategies ...
Non-small cell lung cancer (NSCLC) is the most frequent subtype of lung cancer and remains a highly ...
SummaryHere, we report that kinase-dead IKKα knockin mice develop spontaneous lung squamous cell car...
KRAS is a GTPase that transmits external signals into the cell to regulate numerous cellular process...
KRAS mutations are found in 15–25 % of patients with lung adenocarcinoma, and they lead to constitu...
KRAS mutations are the most frequent gain-of-function alterations in patients with lung adenocarcino...
Lung cancer is the leading cause of cancer death in both men and women in the United States and worl...
Trabajo presentado en el Ciclo de conferencias CIC, celebrada en modalidad virtual el 13 de mayo de ...
: Non-small cell lung cancer (NSCLC) represents the perfect paradigm of 'precision medicine' due to ...
A greater understanding of non–small-cell lung cancer at a molecular level has led to the identifica...
Objectives: The ability of tumor cells to drive angiogenesis is an important cancer hallmark that po...
Although oncogenic activation of NFkB has been identified in various tumors, the NFkB–activating kin...
Lung cancer is a highly mutated tumour type in which, if effective, cancer immunotherapies have prov...
Although oncogenic activation of NF kappa B has been identified in various tumors, the NF kappa B-ac...
Although oncogenic activation of NFkB has been identified in various tumors, the NFkB–activating kin...
For decades, KRAS mutant lung adenocarcinomas (LUAD) have been refractory to therapeutic strategies ...
Non-small cell lung cancer (NSCLC) is the most frequent subtype of lung cancer and remains a highly ...
SummaryHere, we report that kinase-dead IKKα knockin mice develop spontaneous lung squamous cell car...
KRAS is a GTPase that transmits external signals into the cell to regulate numerous cellular process...
KRAS mutations are found in 15–25 % of patients with lung adenocarcinoma, and they lead to constitu...
KRAS mutations are the most frequent gain-of-function alterations in patients with lung adenocarcino...
Lung cancer is the leading cause of cancer death in both men and women in the United States and worl...
Trabajo presentado en el Ciclo de conferencias CIC, celebrada en modalidad virtual el 13 de mayo de ...
: Non-small cell lung cancer (NSCLC) represents the perfect paradigm of 'precision medicine' due to ...
A greater understanding of non–small-cell lung cancer at a molecular level has led to the identifica...